Tiamat Sciences, a Durham, NC-based female-owned biotech startup, raised a seed extension of $2M.
The round, which brought the total fund raised to $5.4M, was led by 8090 Industries with participation from True ventures, Social impact capital, Cantos, Portfolia, Alexandria, Siddhi Capital, Sara Murray, Seed folio, Sustainable Food Ventures and Exponential Impact.
Led by France-Emmanuelle Adil, Founder and CEO, Tiamat Sciences is reinventing recombinant proteins to accelerate the next generation of biotech companies across cellular agriculture, regenerative medicine, vaccine production, and more. Using plants, the company provides animal-free recombinant proteins at a fraction of their cost with a reduced carbon footprint.
The new funds will accelerate product validation in the cellular agriculture and regenerative medicine markets and establish strategic partnerships with industry leaders.
Tiamat Sciences is preparing for production in March 2023 to commercialize its products and for their next round of funding in 2023 to achieve the site expansion in North Carolina and Belgium ahead of schedule, continuing to supply the growing demand of growth factors.
FinSMEs
09/03/2023